PeptideAmerica

Neuropeptides

Semax

US status
PCAC-recommended · pending
Class
Neuropeptides
Approved product
None
Route
None lawful; sold as research-use-only material

Regulatory record

April 2026
Removed from Category 2 without Category 1 listing.
July 2026
PCAC votes 8–5 (one abstention) to recommend 503A listing; advisory only.
FDA final action
None as of August 2026.

Status verified for this index · August 2026

Definition

Semax is a synthetic heptapeptide built from the ACTH(4–7) fragment of adrenocorticotropic hormone with a proline-glycine-proline tail added for stability. It was developed in Moscow in the 1980s and is a registered prescription drug in Russia, given as a nasal spray for stroke recovery and cognitive complaints.

That registration is the molecule's defining fact and its defining asterisk: Semax has never been reviewed by FDA, and a drug approved abroad holds no US marketing status of any kind.

Evidence

The mechanistic literature is real: Semax raises brain-derived neurotrophic factor and trkB receptor expression in rat hippocampus [1] and binds brain tissue with measurable specificity [2]. The clinical literature, by contrast, lives almost entirely in Russian-language journals — a representative modern example followed 110 post-stroke patients through rehabilitation with Semax, tracking plasma BDNF and functional scores [3].

None of this record has passed through FDA review, and no English-language randomized trial supports a cognitive-enhancement use. The nootropic market sells the compound on the Russian dossier's reputation rather than on evidence an American regulator has examined.

Lawful access

Semax was removed from Category 2 of the interim 503A bulks list in April 2026 without Category 1 listing. In July 2026 the Pharmacy Compounding Advisory Committee voted 8–5, with one abstention, to recommend adding it to the section 503A list. The vote is advisory; no FDA final rule has issued, and no licensed pharmacy may lawfully compound Semax as of August 2026.

Nasal sprays and vials sold to US buyers today are research-use-only or gray-market imports, outside pharmacy oversight; the pending page tracks the rulemaking that could change the compounding question.

References

  1. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54–60. PMID 16996037
  2. Dolotov OV, Karpenko EA, Seredenina TS, et al. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006;97 Suppl 1:82–86. PMID 16635254
  3. Gusev EI, Martynov MY, Kostenko EV, Petrova LV, Bobyreva SN. [The efficacy of semax in the treatment of patients at different stages of ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3 Pt 2):61–68. Russian. PMID 29798983